Company performance
Add to research
Current Price
as of Mar 12, 2025$17.71
P/E Ratio
N/A
Market Cap
$543.11M
- EXPO
Description
Add to research
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerANAB
- Price$17.71+0.97%
Trading Information
- Market cap$543.11M
- Float92.27%
- Average Daily Volume (1m)785,201
- Average Daily Volume (3m)958,574
- EPS-$5.12
Company
- Revenue$91.28M
- Rev growth (1yr)432.03%
- Net income-$145.23M
- Gross margin97.37%
- EBITDA margin-123.30%
- EBITDA-$112.55M
- EV$359.87M
- EV/Revenue3.94
- P/EN/A
- P/S5.51
- P/B7.62
- Debt/Equity521.34
Documents
Add to research
SEC Filings
Factset Street Account